332 related articles for article (PubMed ID: 20048183)
21. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
[TBL] [Abstract][Full Text] [Related]
22. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
[TBL] [Abstract][Full Text] [Related]
23. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
24. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Miggiano MC; Gherlinzoni F; Rosti G; Bandini G; Visani G; Fiacchini M; Ricci P; Testoni N; Motta MR; Geromin A; Rizzi S; Belardinelli A; Mangianti S; Manfroi S; Tura S
Leukemia; 1996 Mar; 10(3):402-9. PubMed ID: 8642854
[TBL] [Abstract][Full Text] [Related]
25. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF; Link E; Di Iulio J; Szer J; Marlton P; Wei AH; Enno A; Schwarer A; Lewis ID; D'Rozario J; Coyle L; Cull G; Campbell P; Leahy MF; Hahn U; Cannell P; Tiley C; Lowenthal RM; Moore J; Cartwright K; Cunningham I; Taper J; Grigg A; Roberts AW; Benson W; Hertzberg M; Deveridge S; Rowlings P; Mills AK; Gill D; Bardy P; Campbell L; Seymour JF;
J Clin Oncol; 2017 May; 35(15):1678-1685. PubMed ID: 28368672
[TBL] [Abstract][Full Text] [Related]
26. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
27. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
[TBL] [Abstract][Full Text] [Related]
28. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
[TBL] [Abstract][Full Text] [Related]
29. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
[TBL] [Abstract][Full Text] [Related]
30. [The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].
Parovichnikova EN; Kliasova GA; Sokolov AN; Troitskaia VV; Kokhno AV; Kuz'mina LA; Shaforostova II; Ryzhko VV; Kravchenko SK; Bondarenko SN; Lapin VA; Pristupa AS; Konstantinova TS; Zagoskina TP; Ialykomov IV; Moskov VI; Anchukova LV; Kaporskaia TS; Volodicheva EM; Kaplanov KD; Kondakova EV; Samoĭlova OS; Gavrilova LV; Kulikov SM; Savchenko VG
Ter Arkh; 2012; 84(7):10-5. PubMed ID: 23038965
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
[TBL] [Abstract][Full Text] [Related]
32. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
33. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
34. Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
Lee SM; Lee WS; Shin HJ; Lee JJ; Sohn SK; Moon JH; Eom HS; Won JH; Lee KH; Lee JH; Kim DY; Yoon SS; Kim I; Jung CW; Kim SJ; Kim H; Lee JH; Ryoo HM; Lee GW; Kim SH; Mun YC; Kim MK; Joo YD;
Ann Hematol; 2013 Aug; 92(8):1101-10. PubMed ID: 23558905
[TBL] [Abstract][Full Text] [Related]
35. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR
Am J Hematol; 2007 Dec; 82(12):1056-62. PubMed ID: 17696203
[TBL] [Abstract][Full Text] [Related]
36. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
Saikia TK; Bakshi A; Bhagwat R; Tawde S; Nair R; Nair CN; Parikh PM
Natl Med J India; 2005; 18(1):12-5. PubMed ID: 15835484
[TBL] [Abstract][Full Text] [Related]
37. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
[TBL] [Abstract][Full Text] [Related]
38. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
40. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
